다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Tuberculosis and respiratory diseases : TRD = 결핵 및 호흡기 질환, v.70 no.1, 2011년, pp.1 - 9
AI-Helper
Community-acquired pneumonia (CAP) is a major cause of morbidity, of mortality, and of expenditure of medical resources. The etiology and antimicrobial susceptibility of CAP pathogens can differ by country. Treatment guidelines need to reflect the needs of individual countries based on pathogen susc...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
| 핵심어 | 질문 | 논문에서 추출한 답변 |
|---|---|---|
| 국내의 감염성 질환으로 인한 사망률은? | 지역사회획득 폐렴은 감염성 질환 중 가장 흔한 사망원인 중의 하나이다. 국내 10대 사망원인 중 감염으로 인한 사망 중 1위에 해당되며, 항생제치료에도 불구하고 사망률이 12∼14%에 이른다. 향후 노인인구의 증가로 인해 폐렴 유병률과 이로 인한 사망률은 증가 추세를 보일 것으로 예상된다. | |
| PSI란 무엇인가? | PSI는 Pneumonia Patient Outcome Research Team(PORT) 연구에서 나온 자료를 분석하여 만든 점수체계이다(Tables 4, 5)10. PSI기준은 사망위험도에 따라 환자를 5단계로 구분하며 각 군의 예측사망률은 Table 3과 같다. | |
| CURB-65란 무엇인가? | CURB-65는 영국흉부학회에서 제시한 폐렴 중증도 지표이다(Table 6)12. 이 지표는 1,068명의 환자를 대상으로 한 다변량 분석으로 사망률을 증가시키는 요인 5가지가 제시되었다. |
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-72.
Sohn JW, Park SC, Choi YH, Woo HJ, Cho YK, Lee JS, et al. Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study. J Korean Med Sci 2006;21:602-7.
Lew WJ, Lee EG, Bai JY, Kim HJ, Bai GH, Ahn DI, et al. An Internet-based surveillance system for tuberculosis in Korea. Int J Tuberc Lung Dis 2006;10:1241-7.
Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004;48:2101-7.
Shin JH, Jung HJ, Kim HR, Jeong J, Jeong SH, Kim S, et al. Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. Antimicrob Agents Chemother 2007;51:2625-7.
Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008;31:107-14.
Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, et al. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. Antimicrob Agents Chemother 2007;51:453-60
Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008;52:348-50.
Fine MJ, Hough LJ, Medsger AR, Li YH, Ricci EM, Singer DE, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997;157:36-44.
Yealy DM, Auble TE, Stone RA, Lave JR, Meehan TP, Graff LG, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005;143:881-94.
Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82
Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002; 166:717-23.
File TM Jr, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community- acquired pneumonia. Curr Med Res Opin 2004;20: 1473-81.
File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007;60:112-20.
Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849-58.
Celis R, Torres A, Gatell JM, Almela M, Rodriguez-Roisin R, Agusti-Vidal A. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988;93: 318-24.
El Moussaoui R, Opmeer BC, de Borgie CA, Nieuwkerk P, Bossuyt PM, Speelman P, et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. Chest 2006;130:1165-72.
Bruns AH, Oosterheert JJ, Prokop M, Lammers JW, Hak E, Hoepelman AI. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis 2007; 45:983-91.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.